Linked Life Data

10879732

Source:http://linkedlifedata.com/resource/pubmed/id/10879732

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-7-17
pubmed:abstractText
Synovial sarcomas (SS) are characterized by a chromosomal translocation t(X;18)(p11.2;q11.2) which usually fuses the SYT gene from chromosome 18 to SSX1 or SSX2 genes on chromosome X. Also, a variant SYT-SSX4 fusion gene has recently been shown in a single SS case. In addition to these cytogenetic changes, bcl-2 expression, as assessed by immunohistochemistry, has been reported to be an almost general constitutive alteration of SS. In the present work, we analyze a series of 36 SS surgical samples (from 34 patients) by RT-PCR for the presence of the SYT-SSX1 or the SYT-SSX2 fusion transcript. The analysis was extended to SYT-SSX4 on SYT-SSX1-negative and SYT-SSX2-negative cases only. Our results showed a significant correlation between the SYT-SSX2 fusion and the monophasic SS histologic subtype. SYT-SSX1 fusion transcripts were present in both monophasic and biphasic tumors. The SYT-SSX4 fusion type was detected in a single monophasic SS. In the same series of SS cases, we also confirmed and extended the previously reported constitutive expression of bcl-2 protein, by using both immunohistochemical and western blot analysis. Moreover, we demonstrated that the BCL-2 gene is not rearranged or amplified at genomic level, indicating that the high levels of bcl-2 expression observed in SS might result from transcriptional activation of the gene and/or protein stabilization. Finally, we show that bcl-2 is not phosphorylated in tumors from patients who had been preoperatively treated with radio/chemotherapy, in tumors from untreated patients, or in an SS cell line (CME-1) after in vitro treatment with cytotoxic concentrations of DNA-damaging agents or taxanes. These data indicate that SS cells are unable to activate an apoptosis pathway involving bcl-2 phosphorylation/inactivation and may provide a possible explanation for the limited effectiveness of conventional pharmacological treatments of this tumor type.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0023-6837
pubmed:author
pubmed:issnType
Print
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
805-13
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10879732-Adolescent, pubmed-meshheading:10879732-Adult, pubmed-meshheading:10879732-Aged, pubmed-meshheading:10879732-Chromosomes, Human, Pair 18, pubmed-meshheading:10879732-Female, pubmed-meshheading:10879732-Gene Rearrangement, pubmed-meshheading:10879732-Genes, bcl-2, pubmed-meshheading:10879732-Humans, pubmed-meshheading:10879732-Male, pubmed-meshheading:10879732-Middle Aged, pubmed-meshheading:10879732-Neoplasm Recurrence, Local, pubmed-meshheading:10879732-Oncogene Proteins, Fusion, pubmed-meshheading:10879732-Phosphorylation, pubmed-meshheading:10879732-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:10879732-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:10879732-Sarcoma, pubmed-meshheading:10879732-Synovial Membrane, pubmed-meshheading:10879732-Transcription, Genetic, pubmed-meshheading:10879732-Tumor Markers, Biological, pubmed-meshheading:10879732-X Chromosome
pubmed:year
2000
pubmed:articleTitle
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma.
pubmed:affiliation
Division of Anatomic Pathology and Cytology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't